Profile of Cadaveric Liver Donors of the OPO-UNICAMP From 2002 to 2006

Boin, I.F.S.F.; Kajikawa, P.; Palmiero, H. O.M.; Zambelli, Hélder; Stucchi, R.S.B.; Leonardi, M.I.; Leonardi, Luiz Sérgio

doi:10.1016/j.transproceed.2008.02.037

Cited by 6 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It appears that increasing donor GGT or AST correlates graft survival among donors with HAA whereas their values have no impact on outcomes when donors have no HAA. These findings have practical implications because deceased donors often present with a HAA, with a prevalence ranging from 12 to 18% [22–24]. A previous HAA should be looked for in donors with high GGT or AST.…”

Section: Discussionmentioning

confidence: 99%

The prognostic significance of serum aspartate transaminase and gamma‐glutamyl transferase in liver deceased donors

et al. 2021

View full text Add to dashboard Cite

The impact of aspartate transaminases (AST) and gamma‐glutamyl transferase (GGT) in serum of deceased donors on outcomes after liver transplantation (LT) is unclear. This study aimed to explore the relationship between donor highest AST value or first donor GGT value and graft survival. All consecutive patients who underwent a primary LT in a single center with available donor AST (N = 1253) and GGT value (N = 1152) were included. There was no significant association between donor AST and 90‐day graft survival. We found a moderate association between GGT and 90‐day graft survival. We found a significant interaction with a donor history of alcohol abuse (HAA). The risk of graft loss was associated with AST and GGT in donors with an HAA but remains unchanged in donors without HAA. There was no difference in graft survival according to donor AST or GGT with a cutoff ≥95th percentile (475 UI/l for AST and 170 UI/l for GGT). However, graft survival was significantly decreased when donors combined GGT ≥ 170 UI/l and HAA (61% at one year). Hepatic grafts from donors with high AST or high GGT but without alcohol history and no additional risk factors can be transplanted in low‐risk recipient.

show abstract

Section: Discussionmentioning

confidence: 99%

The prognostic significance of serum aspartate transaminase and gamma‐glutamyl transferase in liver deceased donors

et al. 2021

View full text Add to dashboard Cite

show abstract

“…These features are significant risk factors leading to cardiovascular and cerebrovascular mortality. Hepatic steatosis is therefore present in many older donors 2. Impairment in cognitive function associated with acute alcohol intoxication is a major factor contributing to mortality from motor vehicle and other accidents.…”

mentioning

confidence: 99%

Clinical significance of annexin A2 downregulation in oral squamous cell carcinoma

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Impairment in cognitive function associated with acute alcohol intoxication is a major factor contributing to mortality from motor vehicle and other accidents. Approximately 12% to 20% of organ donations stem from injuries precipitated by alcohol use,2 and many of these individuals are found to have hepatic steatosis 3. As a result, hepatic steatosis is found in about 15% to 25% of potential organ donors.…”

mentioning

confidence: 99%

Impact of the donor liver with steatosis in patients with hepatitis C virus: Not so FAst

Yılmaz

Shiffman

2009

Liver Transpl

View full text Add to dashboard Cite

It is currently estimated that 20% to 25% of the adult population has nonalcoholic fatty liver disease. 1 Hepatic steatosis is one of the features of metabolic syndrome, which includes diabetes mellitus, hypercholesterolemia, and hypertension. These features are significant risk factors leading to cardiovascular and cerebrovascular mortality. Hepatic steatosis is therefore present in many older donors. 2 Impairment in cognitive function associated with acute alcohol intoxication is a major factor contributing to mortality from motor vehicle and other accidents. Approximately 12% to 20% of organ donations stem from injuries precipitated by alcohol use, 2 and many of these individuals are found to have hepatic steatosis. 3 As a result, hepatic steatosis is found in about 15% to 25% of potential organ donors.The negative impact of severe hepatic steatosis on graft dysfunction during the immediate posttransplant period has long been recognized. 4-6 Donor livers containing greater than 30% to 50% steatosis are at increased risk of developing primary nonfunction and delayed function and are associated with reduced graft and patient survival. Historically, these livers were not routinely used for liver transplantation (LT) unless the potential recipient was critically ill and/or the transplant team was willing to accept these risks. Persons with significant hepatic steatosis have also been excluded as candidates for living liver donation because of similar concerns. 7,8 Over the past decade, the number of patients on the LT waiting list, the waiting time to receive a donor liver, and pre-LT mortality have all increased. 9 In an effort to blunt this trend, the use of so-called marginal donor livers, including those with significant steatosis, has increased substantially.Chronic hepatitis C virus (HCV) is the most common indication for LT. 9 Nearly half of all LT recipients in North and South America, Europe, and Australia develop cirrhosis and/or hepatocellular carcinoma secondary to chronic HCV. 9,10 The recurrence of chronic HCV following LT is universal, and progression to advanced bridging fibrosis or cirrhosis occurs in approximately 30% of these patients within 5 years and in approximately 40% within 10 years of LT. 11,12 Numerous studies have attempted to define those factors that are associated with progressive fibrosis in LT recipients with recurrent HCV. 11-17 Many different factors have been implicated in various studies. However, the one consistent finding in nearly all of these studies has been allograft rejection and its subsequent treatment with either high-dose steroids and/or monoclonal antibody preparations. Hepatic steatosis is known to lead to more rapid fibrosis progression in patients with chronic HCV, 18 and a recent study has demonstrated that this also contributes to progressive fibrosis of the LT allograft in patients with recurrent HCV. 11 Several studies have examined the impact of steatosis within the donor graft on the severity of recurrent HCV and/or survival following LT. [19][20][21][22]...

show abstract

Profile of Cadaveric Liver Donors of the OPO-UNICAMP From 2002 to 2006

Cited by 6 publications

References 16 publications

The prognostic significance of serum aspartate transaminase and gamma‐glutamyl transferase in liver deceased donors

The prognostic significance of serum aspartate transaminase and gamma‐glutamyl transferase in liver deceased donors

Clinical significance of annexin A2 downregulation in oral squamous cell carcinoma

Impact of the donor liver with steatosis in patients with hepatitis C virus: Not so FAst

Contact Info

Product

Resources

About